Melanoma-associated antigen pool (MAA pool)

The melanoma-associated antigen (MAA) pool refers to a collection of proteins typically overexpressed in melanoma cells, such as MAGE-1, MAGE-3, MART-1, gp100, and Tyrosinase, which serve as targets for immunotherapy (PubMed: 11590135). In the context of dendritic cell (DC) vaccines, these antigens are presented to the immune system by autologous DCs that have been modified with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and the co-stimulatory molecule B7-2 (CD86) to enhance their potency (NCT00003889). GM-CSF promotes the maturation and recruitment of DCs, while B7-2 provides the necessary secondary signal for robust T-cell activation (PubMed: 12114430). This therapeutic approach aims to overcome the immunosuppressive environment of the tumor and induce a polyvalent cytotoxic T-lymphocyte response capable of recognizing multiple epitopes on melanoma cells. By targeting a pool of antigens rather than a single one, the strategy reduces the risk of tumor escape through antigen loss, offering a more comprehensive treatment for advanced or metastatic melanoma.

Other names

Melanoma antigen poolMelanoma-associated antigensMAAsTumor-associated antigens (TAAs) in melanomaMelanoma peptide cocktail

The vaccine works by delivering a cocktail of melanoma antigens to the immune system via dendritic cells that have been optimized with GM-CSF for maturation and B7-2 for co-stimulation, thereby priming and expanding tumor-specific cytotoxic T lymphocytes (CTLs) to recognize and destroy melanoma cells.